Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 1

Conditions

Primary Myelofibrosis 19Myeloproliferative Disorders 16Polycythemia Vera 10Leukemia 8Leukemia, Myeloid, Acute 7Breast Neoplasms 6Pancreatic Neoplasms 5Myelodysplastic Syndromes 5Hematologic Diseases 5Thrombocythemia, Essential 4Multiple Myeloma 4Bone Marrow Diseases 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Neoplasms 3Myelodysplastic-Myeloproliferative Diseases 3Leukemia, Myelomonocytic, Chronic 3Graft vs Host Disease 3Thrombocytosis 2Prostatic Neoplasms 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Lymphoma 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Bronchiolitis Obliterans Syndrome 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Preleukemia 1Precancerous Conditions 1Pathologic Complete Response 1

Interventions

Tacrolimus 29fludarabine phosphate 21Methotrexate 21Cyclophosphamide 21Mycophenolic Acid 18Busulfan 15Antilymphocyte Serum 14Whole-Body Irradiation 13Sirolimus 12fludarabine 11Peripheral Blood Stem Cell Transplantation 11Cyclosporine 9thymoglobulin 8Melphalan 8Hematopoietic Stem Cell Transplantation 6Granulocyte Colony-Stimulating Factor 6Filgrastim 6Rituximab 5Pentostatin 5Methylprednisolone 5Thiotepa 4Stem Cell Transplantation 4Radiotherapy 4Cyclosporins 4ruxolitinib 3Vorinostat 3Transplantation 3Flow Cytometry 3Etoposide 3merphos 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × Graft vs Host Disease × ruxolitinib × Clear all
NCT03774082 2025-12-11

REACH 5

Novartis

Phase 2 Completed
46 enrolled 21 charts
Lymphoid

Bronchiolitis Obliterans Syndrome, Graft vs Host Disease, Lymphoma, Follicular

NCT03112603 2025-08-12

A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)

Incyte Corporation

Phase 3 Completed
330 enrolled 32 charts 1 FDA

Bronchiolitis Obliterans Syndrome, Graft vs Host Disease

NCT02953678 2021-11-24

A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH-1)

Incyte Corporation

Phase 2 Completed
71 enrolled 24 charts 1 FDA

Graft vs Host Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡